Mepacrine

ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS

Key facts

Mepacrine is a drug catalogued in DrugCentral. It was first approved by the YEAR INTRODUCED in 1933. DrugCentral lists 27 molecular targets, including Prnp, Riboflavin-binding protein and CHRM3. Recorded indications include Giardiasis.

• Molecular targets: Prnp, Riboflavin-binding protein, CHRM3 and CHRM4 (27 listed in DrugCentral).
• Indications: Giardiasis.
• ATC code: P01AX05 (Other agents against amoebiasis and other protozoal diseases).
• Molecular formula: C23H30ClN3O; molecular weight 399.96 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Giardiasis

Off-label uses (2)

• Discoid lupus erythematosus
• Pneumothorax

Mechanism & targets

Molecular targets (27)

Target	Gene	Action	Activity
Major prion protein	Prnp	unknown	IC50 7.02
Riboflavin-binding protein	—	unknown	Kd 6.58
Muscarinic acetylcholine receptor M3	CHRM3	unknown	Ki 6.58
Muscarinic acetylcholine receptor M4	CHRM4	unknown	Ki 6.56
Major prion protein	PRNP	unknown	EC50 6.52
Muscarinic acetylcholine receptor M2	CHRM2	unknown	Ki 6.46
Muscarinic acetylcholine receptor M1	CHRM1	unknown	Ki 6.45
D(3) dopamine receptor	DRD3	unknown	Ki 6.35
Alpha-2C adrenergic receptor	ADRA2C	unknown	Ki 6.25
5-hydroxytryptamine receptor 2A	HTR2A	unknown	Ki 6.12
Alpha-2B adrenergic receptor	ADRA2B	unknown	Ki 6.08
Alpha-2A adrenergic receptor	ADRA2A	unknown	Ki 6.07
Alpha-1D adrenergic receptor	ADRA1D	unknown	Ki 5.99
Alpha-1B adrenergic receptor	Adra1b	unknown	Ki 5.72
Acetylcholinesterase	ACHE	unknown	IC50 5.57
Muscarinic acetylcholine receptor M5	CHRM5	unknown	Ki 5.57
Sodium-dependent noradrenaline transporter	SLC6A2	unknown	Ki 5.54
Aldehyde oxidase	AOX1	unknown	IC50 5.48
Sodium channel alpha subunits; brain (Types I, II, III)	SCN1A|SCN2A|SCN3A	unknown	IC50 5.48
Histamine H2 receptor	HRH2	unknown	Ki 5.46

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1933-01-01	YEAR INTRODUCED	—	—

ATC classification

ATC code	Therapeutic hierarchy
P01AX05	ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS › ANTIPROTOZOALS › AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES › Other agents against amoebiasis and other protozoal diseases

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Lupus vasculitis	211.5
Lupus nephritis	158.8
Mitral valve incompetence	103.1

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Mepacrine is on its molecule page.

• Molecular formula: C₂₃H₃₀ClN₃O
• Molecular weight: 399.96 g/mol
• CAS number: 83-89-6
• InChIKey: GPKJTRJOBQGKQK-UHFFFAOYSA-N
• PubChem CID: 237

CCN(CC)CCCC(C)NC1=C2C=C(OC)C=CC2=NC2=CC(Cl)=CC=C12

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Mepacrine used for?

DrugCentral lists the following indications for Mepacrine: Giardiasis.

How does Mepacrine work?

Its molecular targets in DrugCentral include Prnp, Riboflavin-binding protein, CHRM3 and CHRM4.

When was Mepacrine first approved?

Mepacrine was first approved by the YEAR INTRODUCED in 1933.

What is the chemical formula of Mepacrine?

Mepacrine has the molecular formula C23H30ClN3O and a molecular weight of 399.96 g/mol.

Sources

• DrugCentral drug card 2338 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL2105615 — compound record and bioactivity
• PubChem CID 237 — chemical identifiers
• DrugBank DB01103 — drug record
• FDA UNII H0C805XYDE — substance identity
• UniProt P20309 (CHRM3) — target protein
• UniProt P08173 (CHRM4) — target protein
• UniProt P04156 (PRNP) — target protein
• UniProt P08172 (CHRM2) — target protein
• UniProt P11229 (CHRM1) — target protein
• UniProt P35462 (DRD3) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.